A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Alprazolam (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms StATES
- Sponsors Engage Therapeutics
- 20 Mar 2018 Status changed from planning to recruiting.
- 04 Oct 2017 New trial record
- 27 Sep 2017 According to an Engage Therapeutics media release, Dr. Jacqueline A. French from the NYU Langone Medical Center, will be the principal investigator of the study.